For example, the National Center for Tumor Diseases-Heidelberg Neuro Master Match (N2M2) (NCT03158389) is a trial currently ongoing where molecularly matched targeted therapies plus RT in patients with newly-diagnosed glioblastoma without MGMT promoter are being evaluated [53]. This evidence concerns the gene MGMT and glioblastoma.